We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
STE posted Q3 adjusted EPS of $2.53, matching estimates, while revenues rose 9.5% yoy to $1.50 billion.
STE saw sales growth across Healthcare, AST and Life Sciences, but gross margin fell 72 bps on higher costs.
STE maintained fiscal 2026 guidance, expecting 8-9% revenue growth and adjusted EPS of $10.15-$10.30.
STERIS plc (STE - Free Report) reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.53, up 9% from the year-ago quarter’s figure. The figure matched the Zacks Consensus Estimate.
The adjustment excludes the impacts of certain non-recurring charges, such as the amortization of acquired intangible assets and acquisition and integration-related charges.
The company’s GAAP EPS was $1.96, up 12% from the year-ago level of $1.75.
STE’s Q3 Revenues in Detail
Revenues of $1.50 billion from continuing operations increased 9.5% year over year. The figure surpassed the Zacks Consensus Estimate by 1.1%.
Organic revenues at constant exchange rate or CER rose 8% year over year.
Following the earnings announcement, STE stock fell 3.6% in after-market trading yesterday. The decline was likely due to investor concerns over the contraction in gross margins.
STE’s Quarterly Performance in Detail
The company operates under three segments — Healthcare, Applied Sterilization Technologies (“AST”) and Life Sciences.
Revenues at Healthcare rose 9% year over year to $1.10 billion (up 8% on a CER organic basis). This reflected an 11% improvement in service revenues, 8% growth in consumable revenues and a 7% rise in capital equipment revenues. The Zacks Consensus Estimate for revenues implies an improvement of 8.1% from the year-ago reported figure.
Revenues from AST improved 11% to $286.6 million (up 8% on a CER organic basis). This reflected 9% growth in service revenues and 103% growth in capital equipment revenues. The Zacks Consensus Estimate for revenues implies an increase of 8.1% year over year.
Revenues from the Life Sciences segment increased 7% to $145.8 million (up 5% year over year on a CER organic basis). This reflected 11% growth in consumable revenues, 7% growth in capital equipment revenues and flat service revenues. The Zacks Consensus Estimate for revenues suggests an increase of 8% year over year.
Margins
The gross profit in the reported quarter was $655.5 million, up 7.4% from the prior-year level. The gross margin contracted 72 basis points (bps) year over year to 43.8% due to a 10.6% increase in the cost of revenues.
STERIS witnessed a 5% year-over-year rise in selling, general and administrative expenses. The figure amounted to $352.3 million. Research and development expenses rose 7.7% to $29.5 million. Adjusted operating expenses totaled $381.8 million, up 5.2% year over year. The adjusted operating margin expanded 23 bps to 18.3%.
STERIS exited the third quarter of fiscal 2026 with cash and cash equivalents of $423.7 million compared with $319.2 million at the end of the fiscal second quarter.
Cumulative net cash provided by operating activities at the end of the fiscal third quarter was $1.01 billion compared with $887.3 million in the year-ago period. Further, the company has a five-year annualized dividend growth rate of 9.94%.
Guidance
STERIS has maintained its 2026 financial guidance.
It still expects revenues from continuing operations to increase approximately 8-9%. The Zacks Consensus Estimate is pegged at $5.93 billion, implying 8.6% growth from fiscal 2025.
Constant currency organic revenues are expected to improve approximately 7-8%.
Adjusted EPS is expected to be in the range of $10.15-$10.30. The Zacks Consensus Estimate for the metric is pegged at $10.23.
Our Take
STERIS ended third-quarter fiscal 2026 on a mixed note, with earnings meeting estimates and revenues beating the same. All business segments experienced growth during the quarter. High single digit top-line growth, combined with cost discipline, is driving meaningful EPS growth despite increased tariff headwinds.
Meanwhile, the expansion of operating margin bodes well for the stock.
STE’s Zacks Rank & Key Picks
STE currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are National Vision (EYE - Free Report) , Boston Scientific (BSX - Free Report) and Prestige Consumer Healthcare (PBH - Free Report) .
National Vision, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2025 adjusted EPS of 13 cents, which topped the Zacks Consensus Estimate by 8.3%. Revenues of $487.3 million beat the Zacks Consensus Estimate by 2.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
EYE’s earnings yield of 5.8% compares favorably with the industry’s 2.8% yield. The company beat on earnings in each of the trailing four quarters, with the average surprise being 2.75%.
Boston Scientific, carrying a Zacks Rank #2 at present, posted fourth-quarter 2025 adjusted EPS of 80 cents, which exceeded the Zacks Consensus Estimate by 2.6%. Revenues of $5.29 billion surpassed the Zacks Consensus Estimate by 0.4%.
BSX has an earnings yield of 3.7% compared with the industry’s 2.3% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, with the average surprise being 7.4%.
Prestige Consumer Healthcare, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 EPS of $1.07, which surpassed the Zacks Consensus Estimate by 10.3%. Revenues of $274.1 million topped the Zacks Consensus Estimate by 6.9%.
PBH has an earnings yield of 7.1% compared with the industry’s 2.8% yield. The company’s earnings outperformed estimates in three of the trailing four quarters and missed in the other one, with the average surprise being 2.8%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
STE Q3 Earnings Meet, Revenues Beat, Stock Dips in Aftermarket Trading
Key Takeaways
STERIS plc (STE - Free Report) reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.53, up 9% from the year-ago quarter’s figure. The figure matched the Zacks Consensus Estimate.
The adjustment excludes the impacts of certain non-recurring charges, such as the amortization of acquired intangible assets and acquisition and integration-related charges.
The company’s GAAP EPS was $1.96, up 12% from the year-ago level of $1.75.
STE’s Q3 Revenues in Detail
Revenues of $1.50 billion from continuing operations increased 9.5% year over year. The figure surpassed the Zacks Consensus Estimate by 1.1%.
Organic revenues at constant exchange rate or CER rose 8% year over year.
Following the earnings announcement, STE stock fell 3.6% in after-market trading yesterday. The decline was likely due to investor concerns over the contraction in gross margins.
STE’s Quarterly Performance in Detail
The company operates under three segments — Healthcare, Applied Sterilization Technologies (“AST”) and Life Sciences.
Revenues at Healthcare rose 9% year over year to $1.10 billion (up 8% on a CER organic basis). This reflected an 11% improvement in service revenues, 8% growth in consumable revenues and a 7% rise in capital equipment revenues. The Zacks Consensus Estimate for revenues implies an improvement of 8.1% from the year-ago reported figure.
Revenues from AST improved 11% to $286.6 million (up 8% on a CER organic basis). This reflected 9% growth in service revenues and 103% growth in capital equipment revenues. The Zacks Consensus Estimate for revenues implies an increase of 8.1% year over year.
Revenues from the Life Sciences segment increased 7% to $145.8 million (up 5% year over year on a CER organic basis). This reflected 11% growth in consumable revenues, 7% growth in capital equipment revenues and flat service revenues. The Zacks Consensus Estimate for revenues suggests an increase of 8% year over year.
Margins
The gross profit in the reported quarter was $655.5 million, up 7.4% from the prior-year level. The gross margin contracted 72 basis points (bps) year over year to 43.8% due to a 10.6% increase in the cost of revenues.
STERIS witnessed a 5% year-over-year rise in selling, general and administrative expenses. The figure amounted to $352.3 million. Research and development expenses rose 7.7% to $29.5 million. Adjusted operating expenses totaled $381.8 million, up 5.2% year over year. The adjusted operating margin expanded 23 bps to 18.3%.
STERIS plc Price, Consensus and EPS Surprise
STERIS plc price-consensus-eps-surprise-chart | STERIS plc Quote
Financial Details
STERIS exited the third quarter of fiscal 2026 with cash and cash equivalents of $423.7 million compared with $319.2 million at the end of the fiscal second quarter.
Cumulative net cash provided by operating activities at the end of the fiscal third quarter was $1.01 billion compared with $887.3 million in the year-ago period. Further, the company has a five-year annualized dividend growth rate of 9.94%.
Guidance
STERIS has maintained its 2026 financial guidance.
It still expects revenues from continuing operations to increase approximately 8-9%. The Zacks Consensus Estimate is pegged at $5.93 billion, implying 8.6% growth from fiscal 2025.
Constant currency organic revenues are expected to improve approximately 7-8%.
Adjusted EPS is expected to be in the range of $10.15-$10.30. The Zacks Consensus Estimate for the metric is pegged at $10.23.
Our Take
STERIS ended third-quarter fiscal 2026 on a mixed note, with earnings meeting estimates and revenues beating the same. All business segments experienced growth during the quarter. High single digit top-line growth, combined with cost discipline, is driving meaningful EPS growth despite increased tariff headwinds.
Meanwhile, the expansion of operating margin bodes well for the stock.
STE’s Zacks Rank & Key Picks
STE currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are National Vision (EYE - Free Report) , Boston Scientific (BSX - Free Report) and Prestige Consumer Healthcare (PBH - Free Report) .
National Vision, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2025 adjusted EPS of 13 cents, which topped the Zacks Consensus Estimate by 8.3%. Revenues of $487.3 million beat the Zacks Consensus Estimate by 2.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
EYE’s earnings yield of 5.8% compares favorably with the industry’s 2.8% yield. The company beat on earnings in each of the trailing four quarters, with the average surprise being 2.75%.
Boston Scientific, carrying a Zacks Rank #2 at present, posted fourth-quarter 2025 adjusted EPS of 80 cents, which exceeded the Zacks Consensus Estimate by 2.6%. Revenues of $5.29 billion surpassed the Zacks Consensus Estimate by 0.4%.
BSX has an earnings yield of 3.7% compared with the industry’s 2.3% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, with the average surprise being 7.4%.
Prestige Consumer Healthcare, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 EPS of $1.07, which surpassed the Zacks Consensus Estimate by 10.3%. Revenues of $274.1 million topped the Zacks Consensus Estimate by 6.9%.
PBH has an earnings yield of 7.1% compared with the industry’s 2.8% yield. The company’s earnings outperformed estimates in three of the trailing four quarters and missed in the other one, with the average surprise being 2.8%.